A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis
Antimicrobial Agents and Chemotherapy · 10.12.2025 · 69 (12)
DOI: 10.1128/aac.00933-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 10.12.2025. Verfasst von Elena Pérez Antón und 3 weiteren Autor:innen. Beteiligte Einrichtung: Trypanosome Molecular Biology Unit, Institut Pasteur, Université Paris Cité, INSERM U1347, Paris, France. Hauptthemen laut MEDLINE: Trypanosomiasis, African, Trypanocidal Agents, Drug Resistance, Trypanosoma brucei gambiense. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Labex.
Abstract (Originalsprache)
The World Health Organization aims to eliminate human African trypanosomiasis caused by Trypanosoma brucei gambiense (gHAT) by 2030. With the decline of reported cases, maintaining active surveillance is essential, including for the potential emergence of drug-resistant parasites. We have developed new highly specific diagnostic tools, using the Cas13a-based Specific High-Sensitivity Reporter Enzymatic UnLOCKing (SHERLOCK) technology, for the detection of drug-resistant genotypes that (i) are already circulating, such as the AQP2/3 (814) chimera providing resistance to pentamidine and melarsoprol or (ii) could emerge, such as the Tb CPSF3 (N 232 H) mutation, associated with acoziborole resistance under laboratory conditions. The AQP2/3 (814) SHERLOCK assay detected RNA from both cultured parasites and field strains isolated from gHAT patients who relapsed following melarsoprol or pentamidine treatment. The CPSF3 (SNV) SHERLOCK assay discriminated between wild-type CPSF3 RNA and CPSF3 bearing a single A-C mutation that confers resistance to acoziborole in vitro . These SHERLOCK assays are amenable for use as a high-throughput screening method to monitor for drug-resistant-associated mutations in Trypanosoma brucei , providing a new molecular tool for epidemiological surveillance during the gHAT elimination phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Trypanosome Molecular Biology Unit, Institut Pasteur, Université Paris Cité, INSERM U1347, Paris, France.
- Trypanosome Transmission Group, Trypanosome Cell Biology Unit, INSERM U1347, Institut Pasteur, Université Paris Cité, Paris, France.
- Parasitology Unit, Institut Pasteur of Guinea, Conakry, Guinea.
ORCID-Profile: Elena Pérez Antón, Annick Dujeancourt-Henry, Brice Rotureau, Lucy Glover
Förderung
- Agence Nationale de la Recherche
- Labex
Zitieren
APA
Pérez Antón, E., Dujeancourt-Henry, A., Rotureau, B., & Glover, L. (2025). A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis. Antimicrobial Agents and Chemotherapy, 69(12). https://doi.org/10.1128/aac.00933-25
Vancouver
Pérez Antón E, Dujeancourt-Henry A, Rotureau B, Glover L. A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis. Antimicrobial Agents and Chemotherapy. 2025;69(12). doi:10.1128/aac.00933-25
BibTeX
@article{PrezAntn2025,
author = {Pérez Antón, Elena and Dujeancourt-Henry, Annick and Rotureau, Brice and Glover, Lucy},
title = {A CRISPR-based diagnostic tool to survey drug resistance in human African trypanosomiasis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {12},
doi = {10.1128/aac.00933-25}
}
EUVIMED